MERSANA THERAPEUTICS

Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path

09 Apr 2021 08:15:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Initiation of UPLIFT Single-Arm Registration Strategy for UpRi in Platinum-Resistant Ovarian Cancer

09 Apr 2021 08:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin (XMT-1536) in AACR Journal Molecular Cancer Therapeutics

15 Mar 2021 10:15:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors

11 Mar 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting

10 Mar 2021 16:35:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

26 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates

19 Feb 2021 08:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

17 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

22 Jan 2021 08:00:00 By Nasdaq GlobeNewswire

Carla Poulson Joins Mersana Therapeutics as Chief Human Resources Officer

19 Jan 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

06 Jan 2021 08:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones

05 Jan 2021 10:00:00 By Nasdaq GlobeNewswire